A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. (May 2013)

• Record Type: Journal Article
• Authors: Rosen, Jeffrey B; Jimenez, Jose G; Pirags, Valdis; Vides, Hella; Hanson, Mary E; Massaad, Rachid; McPeters, Gail; Brudi, Philippe; Triscari, Joseph
• Is Part Of: Diabetes & vascular disease research. Volume 10:Number 3(2013)
• Page Start: 277
• Page End: 286
• Publication Date: 2013-05
• Subjects: Ezetimibe/simvastatin -- atorvastatin -- rosuvastatin -- diabetes -- cardiovascular disease (CVD); Diabetic angiopathies -- Periodicals; 616.462005
• DOI: 10.1177/1479164112465212
• Languages: English
• ISSNs: 1479-1641

Abstract

The low-density lipoprotein cholesterol (LDL-C) lowering efficacy of switching to ezetimibe/simvastatin (EZ/S) 10/20 mg versus doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg in subjects with cardiovascular disease (CVD) and diabetes was assessed. Endpoints included percentage change in LDL-C and percentage of patients achieving LDL-C <70 mg/dL. Significantly greater reductions in LDL-C occurred when switching to EZ/S versus statin doubling in the overall population and in subjects treated with simvastatin 20 mg or atorvastatin 10 mg (all p < 0.001). The LDL-C reduction was numerically greater when switching to EZ/S versus switching to rosuvastatin ( p = 0.060). Significantly more subjects reached LDL-C <70 mg/dL with EZ/S (54.5%) versus statin doubling (27.0%) or rosuvastatin (42.5%) in the overall population (all p < 0.001) and within each stratum (all p < 0.001). Switching to EZ/S provided significantly greater reductions in LDL-C versus statin doubling and significantly greater achievement of LDL-C targets versus statin doubling or switching to rosuvastatin.